SELECT id, `name`, primary_key, `key`, treemapgroup, name_cn, zacks_table_name, compare_key, compare_display_name from gurufocu_main.financial_definition where termpagedisplay=1 and `key` = 'Revenue' ATRI (Atrion) Revenue
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Atrion Corp (NAS:ATRI) » Definitions » Revenue

Atrion (Atrion) Revenue

: $169.3 Mil (TTM As of Dec. 2023)
View and export this data going back to 1972. Start your Free Trial

Atrion's revenue for the three months ended in Dec. 2023 was $43.6 Mil. Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $169.3 Mil. Atrion's Revenue per Share for the three months ended in Dec. 2023 was $24.75. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $96.13.

Warning Sign:

Atrion Corp revenue per share is in decline over the past 12 months.

During the past 12 months, the average Revenue per Share Growth Rate of Atrion was -6.20% per year. During the past 3 years, the average Revenue per Share Growth Rate was 6.20% per year. During the past 5 years, the average Revenue per Share Growth Rate was 4.50% per year. During the past 10 years, the average Revenue per Share Growth Rate was 3.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Atrion's highest 3-Year average Revenue per Share Growth Rate was 56.10% per year. The lowest was -54.80% per year. And the median was 6.40% per year.


Atrion Revenue Historical Data

The historical data trend for Atrion's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atrion Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 155.07 147.59 165.01 183.51 169.33

Atrion Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Revenue Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 42.86 39.99 43.84 41.91 43.58

Competitive Comparison

For the Medical Instruments & Supplies subindustry, Atrion's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Atrion Revenue Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Atrion's Revenue distribution charts can be found below:

* The bar in red indicates where Atrion's Revenue falls into.



Atrion Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $169.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Atrion  (NAS:ATRI) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Atrion Revenue Related Terms

Thank you for viewing the detailed overview of Atrion's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Atrion (Atrion) Business Description

Traded in Other Exchanges
N/A
Address
One Allentown Parkway, Allen, TX, USA, 75002-4211
Atrion Corp develops and manufactures products for medical applications. Its fluid-delivery products contribute the largest proportion of revenue and include valves that can hold and release controlled amounts of fluids or gases and are often used in anesthesia and oncology applications. Atrion's cardiovascular products include the MPS2 Myocardial Protection System, which delivers fluids and medications, mixes drugs, and controls temperature and pressure during open-heart surgery. The cardiovascular business also sells cardiac-surgery vacuum relief valves, inflation devices, and other products used in heart surgery. The firm's ophthalmic products include medical devices that disinfect contact lenses. Atrion generates the majority of revenue in the United States.
Executives
Preston G Athey director ONE ALLENTOWN PKWY, ALLEN TX 75002
David A Battat officer: President & CEO 2700 HALKEY-ROBERTS PLACE NORTH, ST. PETERSBURG FL 33716-4103
Jeannette Bankes director ONE ALLENTOWN PARKWAY, ONE ALLENTOWN PARKWAY, ALLEN TX 75002
Morgan Hugh J Jr director
Ronald Nicholas Spaulding director ONE ALLENTOWN PARKWAY, ALLEN TX 75002
Cindy Ferguson officer: Officer/ CFO ONE ALLENTOWN PARKWAY, ALLEN TX 75002
Jeffery Strickland officer: Vice President & CFO
Emile A Battat director, officer: Chairman ONE ALLENTOWN PARKWAY, ALLEN TX 75002
Maria Sainz director C/O ORTHOFIX INTERNATIONAL N. V., 3451 PLANO PARKWAY, LEWISVILLE TX 75056
Stupp John P Jr director STUPP JOHN P JR, #18 ST. ANDREWS DR., ST LOUIS MO 63124
Roger F Stebbing director
Ronald N Spaulding director C/O GUIDANT CORP, 111 MONUMENT CIRCLE #2900, INDIANAPOLIS IN 46204-5129
Richard O Jacobson director ONE ALLENTOWN PARKWAY, C/O ATRION, ALLEN TX 75002
Maley John H P director 6 ROCK CREST LANE, SIGNAL MOUNTAIN TN 37377
Margaret Maxwell Zagel director C/O TELLABS OPERATIONS INC, 4951 INDIANA AVE, LISLE IL 60532

Atrion (Atrion) Headlines

From GuruFocus

Atrion Corporation Declares Quarterly Cash Dividend

By GuruFocusNews GuruFocusNews 07-03-2022

Atrion Corporation Declares Quarterly Cash Dividend

By Value_Insider Value_Insider 11-14-2022

Atrion Reports Third Quarter 2022 Results

By Value_Insider Value_Insider 11-08-2022

Atrion Reports Second Quarter 2022 Results

By PurpleRose PurpleRose 08-08-2022

Atrion Corporation Declares Quarterly Cash Dividend

By GuruFocusNews GuruFocusNews 02-25-2022

Atrion Reports First Quarter 2022 Results

By GuruFocusNews GuruFocusNews 07-08-2022

Atrion Corporation Increases Quarterly Cash Dividend by 11%

By Marketwired Marketwired 08-30-2021

Atrion Reports Second Quarter 2023 Results

By Marketwired 08-08-2023

Atrion Corporation Increases Quarterly Cash Dividend by 10%

By GlobeNewswire GlobeNewswire 08-22-2022